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Abstract 
In patients with chronic obstructive pulmonary disease (COPD), over-activated T-lymphocytes produce pro-inflamma-
tory cytokines and proliferate in situ in the lower airways and pulmonary parenchyma, contributing substantially to 
the pathogenesis of the disease. Despite our understanding of the molecular mechanisms by which lymphocytes are 
activated, we know little about the physiological mechanisms. T-lymphocytes predominantly express delayed rectifier 
K+-channels (Kv1.3) in their plasma membranes and these channels play crucial roles in inducing the lymphocyte 
activation and proliferation. In the pathogenesis of chronic inflammatory diseases, such as chronic kidney disease 
(CKD) or inflammatory bowel disease (IBD), these channels, which are overexpressed in proliferating lymphocytes 
within the inflamed organs, are responsible for the progression of the diseases. Since the over-activation of cellular 
immunity is also mainly involved in the pathogenesis of COPD, this disease could share similar pathophysiological 
features as those of CKD or IBD. From a literature review including ours, it is highly likely that the Kv1.3-channels are 
overexpressed or over-activated in T-lymphocytes isolated from patients with COPD, and that the overexpression of 
the channels would contribute to the development or progression of COPD. The involvement of the channels leads to 
novel therapeutic implications of potentially useful Kv1.3-channel inhibitors, such as calcium channel blockers, mac-
rolide antibiotics, HMG-CoA reductase inhibitors and nonsteroidal anti-inflammatory drugs, in the treatment of COPD.
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T‑lymphocytes in the pathogenesis of COPD
Chronic obstructive pulmonary disease (COPD) is one 
of the leading causes of morbidity and mortality in the 
world, due to increased cigarette smoking, environmen-
tal exposure to air pollution particles and occupational 
exposure to various types of dust and fumes [1, 2]. This 
disease is histopathologically characterized by chronic 
inflammation of the airways, with large numbers of 
inflammatory leukocytes, such as lymphocytes, neutro-
phils, eosinophils, macrophages and mast cells, infiltrat-
ing into the central or peripheral airways [3–7]. These 
inflammatory cells initially trigger the inflammatory 
response in the bronchi or bronchioles, which subse-
quently leads to fibrosis in the smaller airways and alveo-
lar destruction, thus contributing to the pathogenesis of 
the disease [4]. Of note, in patients with COPD, a promi-
nent increase was found in the total numbers of T-lym-
phocytes and their production of pro-inflammatory 
cytokines, such as interferon-γ and tumor necrosis factor 
(TNF), in the airways and lung parenchyma [8]. Among 
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T-lymphocytes, CD8+ cells, which are more predomi-
nant than CD4+ cells in COPD patients, have the capac-
ity to cause cytolysis and apoptosis of alveolar epithelial 
cells through the release of perforins, granzyme-B and 
TNF [9]. Therefore, the increased number of T-lympho-
cytes and their activity actually correlated well with the 
severity of airway obstruction and the amount of alveolar 
destruction in COPD [4].
Involvement of lymphocyte Kv1.3‑channels 
in chronic inflammatory diseases
T-lymphocytes, such as CD4+ and CD8+ cells, predomi-
nantly express delayed rectifier K+-channels (Kv1.3) in 
their plasma membranes [10, 11]. Patch-clamp studies 
revealed that the channels play crucial roles in facilitat-
ing the calcium influx necessary to trigger the lympho-
cyte activation and proliferation [11, 12]. In pathological 
conditions, such as in chronic kidney disease (CKD) or 
inflammatory bowel disease (IBD), the channels were 
overexpressed in proliferating lymphocytes within the 
inflamed kidneys or intestines, and the over-activation of 
the channels largely contributed to the progression of the 
diseases [13–15]. Previously, we demonstrated in an ani-
mal study that the overexpression of Kv1.3-channels in 
lymphocytes was deeply associated with their in situ pro-
liferation in kidneys and the progression of chronic renal 
failure (CRF) [13]. In this study, we further demonstrated 
that margatoxin, a selective inhibitor of the Kv1.3-chan-
nels [16], actually ameliorated the progression of renal 
fibrosis in rat models with advanced CRF [13]. Along 
with COPD, CKD and IBD are also nowadays catego-
rized as chronic inflammatory diseases, in which chronic 
inflammation or the overstimulation of cellular immunity 
is responsible for the pathogenesis [17]. Therefore, these 
diseases could share similar pathophysiological features 
as those of COPD.
Involvement of lymphocyte Kv1.3‑channels 
in COPD
Airway smooth muscle cells express various types of 
K+-channels, such as ATP-sensitive K+-channels and 
large- or intermediate- conductance Ca2+-activated K+-
channels, which play roles in airway hypersensitivity 
and the bronchodilation [18]. Therefore, targeting these 
channels, previous studies revealed the therapeutic use-
fulness of the channel inhibitors or the openers in the 
treatment of COPD [19]. Recently, isolating T-lympho-
cytes from the airways or peripheral blood of patients 
with asthma, Koshy et  al. demonstrated the increased 
expression or activity of Kv1.3-channels in these cells 
[20]. Using a rat model of asthma, they further demon-
strated that the administration of ShK-186, a selective 
inhibitor of the channel, suppressed the proliferation of 
lymphocytes and their cytokine production, and thus 
actually reduced the airway hyper-responsiveness. The 
bronchial inflammation of asthma is characterized by the 
increase in CD4+ T-lymphocytes and their production of 
pro-inflammatory cytokines, while that of COPD is char-
acterized by the predominance of CD8+ T-lymphocytes 
or macrophages [8]. However, the absolute number of 
CD4+ T-lymphocytes is also increased in the airways of 
COPD patients, and they are known to play roles in per-
petuating the inflammatory process [21]. Additionally, 
recent patch-clamp studies demonstrated that the Kv1.3-
channels are predominantly expressed in both types of 
T-lymphocytes [10]. Since the over-activation of cellular 
immunity and its perpetuation in the airways is responsi-
ble for the pathogenesis of COPD [8], the Kv1.3-channels 
in either CD4+ or CD8+ T-lymphocytes are very likely 
to be over-activated or overexpressed in these patients 
(Fig. 1).
Potential future studies
To substantiate the hypothesis that the activity of Kv1.3 
expressed in lymphocytes is important in the pathogen-
esis in COPD, T-lymphocytes could be isolated from the 
airways of COPD patients. As previously described by 
Pizzichini et  al. [22], spontaneous or induced sputum 
and peripheral blood samples could be obtained from 
patients with COPD and from healthy volunteers. Using 
the isolated lymphocytes, the patch-clamp recording 
technique could be applied to identify the Kv1.3-channels 
by detecting the voltage-dependent activation and inacti-
vation patterns characteristic to Kv1.3 [16, 23–27]. Then, 
using these cells, how the selective blocking of the chan-
nels by the drugs, such as margatoxin or ShK-186 [20, 
28], affected the activation or proliferation of the lym-
phocytes could be examined in  vitro. To determine the 
effects of these drugs on the lymphocyte activation kinet-
ics, detailed functional analyses will be required. Possible 
approaches could include measurement of the cytokine 
production [29], leukocyte migration assay [28] and the 
measurement of [3H] thymidine incorporation into the 
lymphocyte DNA [20]. The proliferation of lymphocytes 
could be detected by either Ki-67 antibody staining or 
5′-bromo-2′-deoxyuridine (BrdU) incorporation assay.
To clarify the roles of lymphocyte Kv1.3-channels in the 
pathogenesis of COPD, the following in vivo experiments 
could be conducted. Based on previous studies, mouse 
or rat models of COPD, such as pulmonary emphysema, 
can be induced by exposure to cigarette-smoke or the 
intra-tracheal instillation of chemical substances, such as 
lipopolysaccharides (LPS), cadmium chloride, nitrogen 
dioxide, inorganic dusts and ozone [30, 31]. Using these 
animal models, the expressional abundance of Kv1.3-
channels in lymphocytes within the airways or lung 
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parenchyma could histologically be examined. To reveal 
the actual involvement of the channels in the pathogen-
esis of COPD, selective inhibitors of the channels, such 
as margatoxin, ShK, Psora-4 or PAP-1 [13, 32–35], could 
therapeutically administered to the animals and quantify 
the production of pro-inflammatory cytokines in the air-
ways or alveolar parenchyma. The degrees of bronchial 
inflammation, small airway fibrosis and alveolar destruc-
tion could also be analyzed histopathologically [36].
Cigarette smoking is by far the most important envi-
ronmental risk factor for the development of COPD. 
However, not all smokers develop COPD, suggesting 
that genetic factors that increase the susceptibility to the 
disease are also important in the pathogenesis of COPD 
[37]. So far, previous linkage analysis studies have iden-
tified many candidate genes that are associated with the 
development of COPD, such as PI MZ α-1 antitrypsin 
gene [38], matrix metalloproteinase 12 (MMP12) [39], 
transforming growth factor β-1 (TGFB1) and glutathione 
S-transferase Mu 1 (GSTM1) [40]. Due to recent devel-
opments in high-throughput genotyping screening tech-
niques, genome-wide association study (GWAS) could 
be performed in a relatively rapid and inexpensive man-
ner [41, 42]. By the case–control basis, this study enables 
to examine a genome-wide panel of single-nucleotide 
polymorphisms (SNPs) in association with phenotypes 
of interest. Recently, using this approach, Ota et al. dem-
onstrated that the polymorphism in the KCNA3 gene, 
which encodes Kv1.3, was associated with the susceptibil-
ity to autoimmune pancreatitis, in which T cell-mediated 
over-activation of cellular immunity is responsible for the 
pathogenesis [43]. The similar approach could be applied 
to detect the genetic variants of the human Kv1.3 gene in 
association with the phenotypes of COPD, such as the 
severity of the disease, the results of lung function tests 
and the findings of chest CT scanning [42]. Such genetic 
variance could also be linked with the epidemiological 
factors of COPD, including its prevalence, morbidity, 
mortality and comorbidity rates [44, 45].
Therapeutic implications of targeting 
Kv1.3‑channels in the treatment of COPD
Kv1.3-channels can be pharmacologically targeted by 
a variety of blockers of the channels [11, 46]. Addition-
ally, in our series of patch-clamp studies, commonly used 
drugs, such as calcium channel blockers (CCBs) [25, 
27], macrolide antibiotics [24], HMG-CoA reductase 
inhibitors (statins) [26] and nonsteroidal anti-inflamma-
tory drugs (NSAIDs) [23], also effectively inhibited the 
Kv1.3-channel currents in thymus-derived murine lym-
phocytes. Of note, benidipine, one of the dihydropyri-
dine-type CCBs, which most strongly and persistently 
inhibited the channel currents [25], actually suppressed 
the proliferation of kidney lymphocytes, and thus amelio-
rated the progression of renal fibrosis [47]. In this regard, 
in addition to using the previously developed selective 
blockers for the channels [48–50], the use of CCBs, mac-
rolide antibiotics or statins could also potentially be use-
ful in the treatment of COPD (Fig. 1).
In recent systematic review, statins were actually 
shown to prevent the exacerbation of COPD and reduce 
the risk of mortality in these patients [51, 52]. This could 
be explained by their pleiotropic effects, including anti-
inflammatory and immunomodulatory effects, which 
was demonstrated by the significant decrease in systemic 
inflammation markers such as C-reactive protein and 
IL-6 [53, 54]. Additionally, statins were demonstrated 
Fig. 1 Roles of Kv1.3-channels in the activation pathway of cellular 
immunity in the respiratory tract and the development of chronic 
obstructive pulmonary disease (COPD). In the initiation of mucosal 
immunity in the airways, bronchial or alveolar macrophages, which 
phagocytose smoke particles, humorally activate T-lymphocytes 
within the lamina propria of the respiratory mucosa. Kv1.3-channels 
expressed on T-lymphocytes stimulate their IL-2 production and cel-
lular proliferation through the activation of calcineurin/NFAT signaling 
pathway. The overexpression of the channels over-stimulates such 
lymphocyte activity, which triggers the development of chronic 
obstructive pulmonary disease. Potential Kv1.3-channel inhibitors, 
such as CCBs, macrolides, statins and NSAIDs may be useful in the 
treatment of COPD. NFAT nuclear factor of activated T cells, CCB cal-
cium channel blocker, NSAID nonsteroidal anti-inflammatory drug
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to regulate the balance between Th1 and Th2 cells by 
inhibiting the Th1 development but augmenting the Th2 
development of CD4+ cells [55]. In addition to statins, 
NSAIDs, such as ibuprofen or indomethacin, were also 
effective in patients with COPD, since these drugs ame-
liorated the production of bronchorrhea in these patients 
by reducing the concentration of prostaglandin E2 in their 
sputum [56]. Using lymphocytes isolated from patients 
with COPD, we would apply the patch-clamp recording 
technique and examine the production of pro-inflamma-
tory cytokines from lymphocytes. Thus, we could reveal 
how the statins or NSAIDs-induced inhibition of Kv1.3-
channels affects the activation of lymphocytes in vitro. To 
further reveal the therapeutic efficacy of these drugs in 
the pathogenesis of COPD, we would administer them to 
the experimental animal models of COPD [30, 31]. Then 
we would quantify the production of pro-inflammatory 
cytokines in the airways or alveolar parenchyma, or his-
topathologically analyze the degrees of bronchial inflam-
mation, small airway fibrosis and alveolar destruction.
Recently, the continuous use of low-dose macrolide 
antibiotics was actually shown to be an effective treat-
ment for COPD [57–59]. In randomized, double-blinded 
and placebo-controlled studies, Suzuki et  al. and See-
mungal et al. demonstrated that long-term erythromycin 
therapy was beneficial in the prevention of COPD exac-
erbations, which eventually contributed to the reduced 
number of hospitalizations [60, 61]. In other prospective, 
parallel-group and placebo-controlled studies, Blasi et al. 
and Albert et  al. additionally revealed that the continu-
ous administration of azithromycin decreased the rate 
of COPD exacerbations, and thus improved the qual-
ity of life of these patients [62, 63]. Besides, in some 
case reports, macrolide antibiotics, such as clarithro-
mycin, ameliorated the extra-pulmonary symptoms of 
Mycoplasma pneumonia infection, such as cold agglu-
tinins-induced hemoglobinuria, which are primarily 
attributable to the increased activity of T-lymphocytes 
[64, 65]. Concerning the therapeutic efficacies of mac-
rolide antibiotics apart from their anti-microbial prop-
erties, several in  vitro studies revealed that macrolide 
antibiotics, such as clarithromycin and azithromycin, 
suppress the production of pro-inflammatory cytokines 
from T-lymphocytes and thus exert immunomodulatory 
effects [66, 67]. In our recent patch-clamp study using 
murine thymocytes, clarithromycin markedly suppressed 
the Kv1.3-channel currents in a dose-dependent manner, 
suggesting its higher potency an useful channel inhibi-
tor [24]. In T-lymphocytes, the Kv1.3-channels trigger 
calcium influx, which is necessary for IL-2 synthesis [11, 
68], and channel blockade by highly selective inhibitors, 
such as margatoxin and ShK-Dap22, actually represses 
the immune response in the cells [28, 69]. Therefore, 
the potency of macrolide antibiotics as a Kv1.3-channel 
inhibitor was likely to be responsible for their immu-
nomodulatory properties that have recently been demon-
strated in the treatment of COPD [57–59].
Conclusion
From our recent findings and the literature review, Kv1.3-
channels are very likely to be overexpressed or over-
activated in T-lymphocytes isolated from patients with 
COPD, which may contribute to the development or pro-
gression of the disease. Based on this, we suggest novel 
therapeutic implications of potentially useful Kv1.3-
channel inhibitors, such as CCBs, macrolide antibiotics, 
statins and NSAIDs, in the treatment of COPD.
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